抗体偶联药物在卵巢癌中的研究进展  

Research progress in antibody-drug conjugates in ovarian cancer

作　　者：荆美玲 俞星[2] JING Mei-ling;YU Xing(Medical College,Yanbian University,Yanji JILIN 133002,China;Department of Preventive Medicine,Medical College,Yanbian University,Yanji JILIN 133002,China)

机构地区：[1]延边大学医学院,吉林延吉133002 [2]延边大学医学院预防医学教研部,吉林延吉133002

出　　处：《中国新药与临床杂志》2024年第11期809-813,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：吉林省卫生健康科技能力提升项目(2021JC064)。

摘　　要：抗体偶联药物(ADC)由单克隆抗体、连接子和细胞毒性药物三部分构成,是兼具靶向特异性与化疗药物杀伤性的新型抗肿瘤药物。ADC不但在乳腺癌、胃癌和肺癌等多个领域卓有成效,在卵巢癌中也有一定的临床获益。本文就ADC的结构、机制及其在卵巢癌中的应用展开综述,旨在为卵巢癌的临床治疗提供新思路。Antibody-drug conjugates(ADCs)consist of monoclonal antibodies,linkers,and cytotoxic drugs,representing a novel class of anti-cancer agents that combine target specificity with chemotherapeutic efficacy.ADCs have demonstrated significant efficacy not only in breast cancer,gastric cancer and lung cancer,and have also shown clinical benefits in ovarian cancer.This review discussed the structure,mechanism,and applications of ADCs in ovarian cancer,aiming to provide new insights for clinical treatment of ovarian cancer.

关 键 词：抗体偶联药物 靶向治疗 卵巢癌 

分 类 号：R979.1[医药卫生—药品]